Alterations in nuclear pore architecture allow cancer cell entry into or exit from drug-resistant dormancy

Am J Pathol. 2012 Jan;180(1):375-89. doi: 10.1016/j.ajpath.2011.09.024. Epub 2011 Nov 7.

Abstract

Phenotypic diversity arises in tumors just as it does in developing organisms, and tumor recurrence frequently manifests from the selective survival of divergent drug-resistant cells. Although the expanding tumor cell population may be successfully targeted, drug-resistant cells may persist and sustain the tumor or enter dormancy before igniting a future relapse. Herein, we show that partial knockdown of nucleoporin p62 (NUP62) by small-interfering RNA confers cisplatin resistance to cultured high-grade ovarian carcinoma cells. Treatment with NUP62 small-interfering RNA and cisplatin leaves resistant cells in a state of dormancy; some dormant cells can be induced to proliferate by transient induction of NUP62 expression from an ectopic expression construct. In addition to suggesting functional links between nuclear pore complex architecture and cancer cell survival, the culture system provides a novel experimental window into the dynamics of tumor cell drug resistance and dormancy.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Antineoplastic Agents / pharmacology*
  • Cell Cycle Checkpoints / drug effects
  • Cell Cycle Checkpoints / genetics
  • Cell Line, Tumor
  • Cell Proliferation
  • Cisplatin / pharmacology*
  • Drug Resistance, Neoplasm / genetics
  • Female
  • Gene Knockdown Techniques
  • Humans
  • Membrane Glycoproteins / genetics
  • Membrane Glycoproteins / metabolism
  • Membrane Glycoproteins / pharmacology*
  • Neoplasm Recurrence, Local / genetics
  • Nuclear Pore / drug effects*
  • Nuclear Pore / genetics
  • Nuclear Pore Complex Proteins / genetics
  • Nuclear Pore Complex Proteins / metabolism
  • Nuclear Pore Complex Proteins / pharmacology*
  • Ovarian Neoplasms / drug therapy*
  • Ovarian Neoplasms / genetics
  • Ovarian Neoplasms / metabolism
  • Phenotype
  • RNA, Small Interfering / genetics
  • RNA, Small Interfering / pharmacology*

Substances

  • Antineoplastic Agents
  • Membrane Glycoproteins
  • Nuclear Pore Complex Proteins
  • RNA, Small Interfering
  • nuclear pore protein p62
  • Cisplatin